{
    "nct_id": "NCT01453569",
    "title": "Phase II Study of Sodium Oligo-mannurarate Capsule on Mild to Moderate Alzheimer Disease",
    "status": "COMPLETED",
    "last_update_time": "2015-01-25",
    "description_brief": "The primary purpose of this study is to determine whether sodium oligo-mannurarate capsule is effective and safe in the treatment of mild to moderate alzheimer' disease, and to determine the best therapeutic dose of sodium oligo-mannurarate capsule.",
    "description_detailed": "Alzheimer's disease is known for placing a great burden on caregivers which includes social, psychological, physical or economic aspects. Research indicates that the disease is associated with plaques and tangles in the brain. Currently used treatments offer a small symptomatic benefit. No treatments to delay or halt the progression of the disease are, as of yet, available. The investigators suppose sodium oligo-mannurarate capsule to be effective to halt the progression of the disease.",
    "phase": [
        "PHASE2"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": {
        "participantFlowModule": {
            "groups": [
                {
                    "id": "FG000",
                    "title": "Sodium Oligo-mannurarate 900mg",
                    "description": "Sodium oligo-mannurarate 900mg: sodium oligo-mannurarate capsule 900mg twice a day for 24 weeks"
                },
                {
                    "id": "FG001",
                    "title": "Sodium Oligo-mannurarate 600mg",
                    "description": "Sodium oligo-mannurarate 600mg: sodium oligo-mannurarate capsule 600mg twice a day for 24 weeks"
                },
                {
                    "id": "FG002",
                    "title": "Placebo",
                    "description": "Placebo: simulant of sodium oligo-mannurarate capsule"
                }
            ],
            "periods": [
                {
                    "title": "Overall Study",
                    "milestones": [
                        {
                            "type": "STARTED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "86"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "84"
                                },
                                {
                                    "groupId": "FG002",
                                    "numSubjects": "85"
                                }
                            ]
                        },
                        {
                            "type": "COMPLETED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "75"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "70"
                                },
                                {
                                    "groupId": "FG002",
                                    "numSubjects": "78"
                                }
                            ]
                        },
                        {
                            "type": "NOT COMPLETED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "11"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "14"
                                },
                                {
                                    "groupId": "FG002",
                                    "numSubjects": "7"
                                }
                            ]
                        }
                    ]
                }
            ]
        },
        "baselineCharacteristicsModule": {
            "populationDescription": "All the treated subjects were evaluated for safety. 2, 8 and 3 subjects were excluded from FAS in placebo, 600 mg and 900 mg group respectively. So the case No. were 83, 76, 83 for placebo, 600 mg and 900 mg group respectively.",
            "groups": [
                {
                    "id": "BG000",
                    "title": "Sodium Oligo-mannurarate 900mg",
                    "description": "Sodium oligo-mannurarate 900mg: sodium oligo-mannurarate capsule 900mg twice a day for 24 weeks"
                },
                {
                    "id": "BG001",
                    "title": "Sodium Oligo-mannurarate 600mg",
                    "description": "Sodium oligo-mannurarate 600mg: sodium oligo-mannurarate capsule 600mg twice a day for 24 weeks"
                },
                {
                    "id": "BG002",
                    "title": "Placebo",
                    "description": "Placebo: simulant of sodium oligo-mannurarate capsule"
                },
                {
                    "id": "BG003",
                    "title": "Total",
                    "description": "Total of all reporting groups"
                }
            ],
            "denoms": [
                {
                    "units": "Participants",
                    "counts": [
                        {
                            "groupId": "BG000",
                            "value": "83"
                        },
                        {
                            "groupId": "BG001",
                            "value": "76"
                        },
                        {
                            "groupId": "BG002",
                            "value": "83"
                        },
                        {
                            "groupId": "BG003",
                            "value": "242"
                        }
                    ]
                }
            ],
            "measures": [
                {
                    "title": "Age, Continuous",
                    "paramType": "MEAN",
                    "dispersionType": "STANDARD_DEVIATION",
                    "unitOfMeasure": "years",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "70.39",
                                            "spread": "8.51"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "70.26",
                                            "spread": "8.40"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "70.34",
                                            "spread": "8.13"
                                        },
                                        {
                                            "groupId": "BG003",
                                            "value": "70.33",
                                            "spread": "8.24"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Sex: Female, Male",
                    "paramType": "COUNT_OF_PARTICIPANTS",
                    "unitOfMeasure": "Participants",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "title": "Female",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "50"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "41"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "52"
                                        },
                                        {
                                            "groupId": "BG003",
                                            "value": "143"
                                        }
                                    ]
                                },
                                {
                                    "title": "Male",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "33"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "35"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "31"
                                        },
                                        {
                                            "groupId": "BG003",
                                            "value": "99"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                }
            ]
        },
        "outcomeMeasuresModule": {
            "outcomeMeasures": [
                {
                    "type": "PRIMARY",
                    "title": "Change of Alzheimer's Disease Assessment Scale-cognitive Subscale(ADAS-cog)/12 After 24 Wks Treatment of Sodium Oligo-mannurarate Capsule",
                    "description": "Alzheimer's Disease Assessment Scale-cognitive Subscale(ADAS-cog)/12 is the most popular cognitive testing instrument used in clinical trials. It consists of 12 tasks measuring the disturbances of memory, language, praxis, attention and other cognitive abilities which are often referred to as the core symptoms of AD. The total score ranges 0-75, the higher score indicates more severity of the disease. Change after 24 wks treatment was calculated by the week 24 minus week 0 (baseline), and a negative change represents an improvement.",
                    "populationDescription": "85, 84, 86 patients were enrolled, and 2, 8 and 3 subjects were excluded from FAS in placebo, 600 mg and 900 mg group respectively. So the case No. ananlysed were 83, 76, 83 for placebo, 600 mg and 900 mg group respectively.",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Error",
                    "unitOfMeasure": "units on a scale",
                    "timeFrame": "24 weeks",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Sodium Oligo-mannurarate 900mg",
                            "description": "Sodium oligo-mannurarate 900mg: sodium oligo-mannurarate capsule 900mg twice a day for 24 weeks"
                        },
                        {
                            "id": "OG001",
                            "title": "Sodium Oligo-mannurarate 600mg",
                            "description": "Sodium oligo-mannurarate 600mg: sodium oligo-mannurarate capsule 600mg twice a day for 24 weeks"
                        },
                        {
                            "id": "OG002",
                            "title": "Placebo",
                            "description": "Placebo: simulant of sodium oligo-mannurarate capsule"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "83"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "76"
                                },
                                {
                                    "groupId": "OG002",
                                    "value": "83"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-2.58",
                                            "spread": "0.62"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "-1.39",
                                            "spread": "0.75"
                                        },
                                        {
                                            "groupId": "OG002",
                                            "value": "-1.45",
                                            "spread": "0.77"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Change of Clinician's Interview-Based Impression of Change Plus(CIBIC-plus) After 24 Wks Treatment of Sodium Oligo-mannurarate Capsule",
                    "description": "Clinician's Interview-Based Impression of Change Plus(CIBIC-plus) is widely used in antidementia drug trials. It comprises Likert scales for disease severity and changes, and written accounts summarizing semistructured interviews evaluating behavior, cognition, and function. The results classified as 7 degrades as: Markedly improved, Moderately improved, Minimally improved, No change, Minimally worse, Moderately worse, and Markedly worse.",
                    "reportingStatus": "POSTED",
                    "paramType": "NUMBER",
                    "unitOfMeasure": "participants",
                    "timeFrame": "24 weeks",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Sodium Oligo-mannurarate 900mg",
                            "description": "Sodium oligo-mannurarate 900mg: sodium oligo-mannurarate capsule 900mg twice a day for 24 weeks"
                        },
                        {
                            "id": "OG001",
                            "title": "Sodium Oligo-mannurarate 600mg",
                            "description": "Sodium oligo-mannurarate 600mg: sodium oligo-mannurarate capsule 600mg twice a day for 24 weeks"
                        },
                        {
                            "id": "OG002",
                            "title": "Placebo",
                            "description": "Placebo: simulant of sodium oligo-mannurarate capsule"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "83"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "76"
                                },
                                {
                                    "groupId": "OG002",
                                    "value": "83"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "title": "Markedly improved",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "2"
                                        },
                                        {
                                            "groupId": "OG002",
                                            "value": "3"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Moderately improved",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "13"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "9"
                                        },
                                        {
                                            "groupId": "OG002",
                                            "value": "6"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Minimally improved",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "29"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "18"
                                        },
                                        {
                                            "groupId": "OG002",
                                            "value": "32"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "No change",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "35"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "23"
                                        },
                                        {
                                            "groupId": "OG002",
                                            "value": "25"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Minimally worse",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "4"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "21"
                                        },
                                        {
                                            "groupId": "OG002",
                                            "value": "17"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Moderately worse",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "2"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "3"
                                        },
                                        {
                                            "groupId": "OG002",
                                            "value": "0"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Markedly worse",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "OG002",
                                            "value": "0"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Change of Alzheimer's Disease Cooperative Study/Activities of Daily(ADCS-ADL) After 24 Wks Treatment of Sodium Oligo-mannurarate Capsule",
                    "description": "Alzheimer's Disease Cooperative Study/Activities of Daily (ADCS-ADL) is a scale assessed the daily activties of AD patients after interviewed the caregiver. The scale mainly assess the eating, walking, writing, bathing and reading, et al of the subject. The total score ranges 0-78, the higher score indicate improvement in daily activities. Change after 24 wks treatment was calculated by the week 24 minus week 0 (baseline), and a positive change represents an improvement.",
                    "populationDescription": "85, 84, 86 patients were enrolled, and 2, 8 and 3 subjects were excluded from FAS in placebo, 600 mg and 900 mg group respectively. So the case No. ananlysed were 83, 76, 83 for placebo, 600 mg and 900 mg group respectively.",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Error",
                    "unitOfMeasure": "units on a scale",
                    "timeFrame": "24 weeks",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Sodium Oligo-mannurarate 900mg",
                            "description": "Sodium oligo-mannurarate 900mg: sodium oligo-mannurarate capsule 900mg twice a day for 24 weeks"
                        },
                        {
                            "id": "OG001",
                            "title": "Sodium Oligo-mannurarate 600mg",
                            "description": "Sodium oligo-mannurarate 600mg: sodium oligo-mannurarate capsule 600mg twice a day for 24 weeks"
                        },
                        {
                            "id": "OG002",
                            "title": "Placebo",
                            "description": "Placebo: simulant of sodium oligo-mannurarate capsule"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "83"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "76"
                                },
                                {
                                    "groupId": "OG002",
                                    "value": "83"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-0.49",
                                            "spread": "0.91"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "-0.47",
                                            "spread": "0.88"
                                        },
                                        {
                                            "groupId": "OG002",
                                            "value": "-1.06",
                                            "spread": "0.85"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Change of Neuropsychiatric Inventory(NPI) After 24 Wks Treatment of Sodium Oligo-mannurarate Capsule",
                    "description": "Neuropsychiatric Inventory (NPI) is a scale to obtain information on the presence of psychopathology in patient with brain disorders. The NPI was developed for application to patients with AD and other dementias, but it may be useful in the assessment of behavioral changes in other conditions. Twelve behavioral areas included in the NPI will be assessed in this trial: delusions, hallucinations, agitation/aggression, depression/dysphoria, anxiety and elation/euphoria, et al. The total score ranges 0 to 120, the higher score indicates worse state of the AD patient. Change after 24wks treatmnt was calculated by the week 24 minus week 0 (baseline), and a negative change represents an improvement.",
                    "populationDescription": "85, 84, 86 patients were enrolled, and 2, 8 and 3 subjects were excluded from FAS in placebo, 600 mg and 900 mg group respectively. So the case No. ananlysed were 83, 76, 83 for placebo, 600 mg and 900 mg group respectively.",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Error",
                    "unitOfMeasure": "units on a scale",
                    "timeFrame": "24 weeks",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Sodium Oligo-mannurarate 900mg",
                            "description": "Sodium oligo-mannurarate 900mg: sodium oligo-mannurarate capsule 900mg twice a day for 24 weeks"
                        },
                        {
                            "id": "OG001",
                            "title": "Sodium Oligo-mannurarate 600mg",
                            "description": "Sodium oligo-mannurarate 600mg: sodium oligo-mannurarate capsule 600mg twice a day for 24 weeks"
                        },
                        {
                            "id": "OG002",
                            "title": "Placebo",
                            "description": "Placebo: simulant of sodium oligo-mannurarate capsule"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "83"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "76"
                                },
                                {
                                    "groupId": "OG002",
                                    "value": "83"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-1.11",
                                            "spread": "1.22"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "0.24",
                                            "spread": "0.83"
                                        },
                                        {
                                            "groupId": "OG002",
                                            "value": "-2.08",
                                            "spread": "0.98"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                }
            ]
        },
        "adverseEventsModule": {
            "frequencyThreshold": "0",
            "eventGroups": [
                {
                    "id": "EG000",
                    "title": "Sodium Oligo-mannurarate 900mg",
                    "description": "Sodium oligo-mannurarate 900mg: sodium oligo-mannurarate capsule 900mg twice a day for 24 weeks",
                    "seriousNumAffected": 3,
                    "seriousNumAtRisk": 86,
                    "otherNumAffected": 3,
                    "otherNumAtRisk": 86
                },
                {
                    "id": "EG001",
                    "title": "Sodium Oligo-mannurarate 600mg",
                    "description": "Sodium oligo-mannurarate 600mg: sodium oligo-mannurarate capsule 600mg twice a day for 24 weeks",
                    "seriousNumAffected": 6,
                    "seriousNumAtRisk": 84,
                    "otherNumAffected": 12,
                    "otherNumAtRisk": 84
                },
                {
                    "id": "EG002",
                    "title": "Placebo",
                    "description": "Placebo: simulant of sodium oligo-mannurarate capsule",
                    "seriousNumAffected": 6,
                    "seriousNumAtRisk": 85,
                    "otherNumAffected": 5,
                    "otherNumAtRisk": 85
                }
            ],
            "seriousEvents": [
                {
                    "term": "Behavioral and psychiatric symptoms",
                    "organSystem": "Psychiatric disorders",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 86
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 84
                        },
                        {
                            "groupId": "EG002",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 85
                        }
                    ]
                },
                {
                    "term": "Osteoarthritis",
                    "organSystem": "Musculoskeletal and connective tissue disorders",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 86
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 84
                        },
                        {
                            "groupId": "EG002",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 85
                        }
                    ]
                },
                {
                    "term": "Subdural hematoma",
                    "organSystem": "Vascular disorders",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 86
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 84
                        },
                        {
                            "groupId": "EG002",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 85
                        }
                    ]
                },
                {
                    "term": "Stroke",
                    "organSystem": "Nervous system disorders",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 86
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 84
                        },
                        {
                            "groupId": "EG002",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 85
                        }
                    ]
                },
                {
                    "term": "Implantation of artificial heart pacemaker",
                    "organSystem": "Cardiac disorders",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 86
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 84
                        },
                        {
                            "groupId": "EG002",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 85
                        }
                    ]
                },
                {
                    "term": "Paralysis of oculomotor nerve",
                    "organSystem": "Nervous system disorders",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 86
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 84
                        },
                        {
                            "groupId": "EG002",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 85
                        }
                    ]
                },
                {
                    "term": "Cellulitis",
                    "organSystem": "Infections and infestations",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 86
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 84
                        },
                        {
                            "groupId": "EG002",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 85
                        }
                    ]
                },
                {
                    "term": "Appendicitis",
                    "organSystem": "Gastrointestinal disorders",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 86
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 84
                        },
                        {
                            "groupId": "EG002",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 85
                        }
                    ]
                },
                {
                    "term": "Emptying disorder of intestine and stomach",
                    "organSystem": "Gastrointestinal disorders",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 86
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 84
                        },
                        {
                            "groupId": "EG002",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 85
                        }
                    ]
                },
                {
                    "term": "Hypertension",
                    "organSystem": "Cardiac disorders",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 86
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 84
                        },
                        {
                            "groupId": "EG002",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 85
                        }
                    ]
                },
                {
                    "term": "Hernia",
                    "organSystem": "General disorders",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 86
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 84
                        },
                        {
                            "groupId": "EG002",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 85
                        }
                    ]
                },
                {
                    "term": "Chill",
                    "organSystem": "General disorders",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 86
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 84
                        },
                        {
                            "groupId": "EG002",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 85
                        }
                    ]
                },
                {
                    "term": "Compressive fracture of vertebra",
                    "organSystem": "Musculoskeletal and connective tissue disorders",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 86
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 84
                        },
                        {
                            "groupId": "EG002",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 85
                        }
                    ]
                },
                {
                    "term": "Lung cancer",
                    "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 86
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 84
                        },
                        {
                            "groupId": "EG002",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 85
                        }
                    ]
                },
                {
                    "term": "Cerebral hemorrhage",
                    "organSystem": "Nervous system disorders",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 86
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 84
                        },
                        {
                            "groupId": "EG002",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 85
                        }
                    ]
                }
            ],
            "otherEvents": [
                {
                    "term": "Ear and labyrinth",
                    "organSystem": "Ear and labyrinth disorders",
                    "notes": "Medication-related AE",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 86
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 84
                        },
                        {
                            "groupId": "EG002",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 85
                        }
                    ]
                },
                {
                    "term": "Gastrointestinal",
                    "organSystem": "Gastrointestinal disorders",
                    "notes": "Medication-related AE",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 86
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 84
                        },
                        {
                            "groupId": "EG002",
                            "numEvents": 4,
                            "numAffected": 4,
                            "numAtRisk": 85
                        }
                    ]
                },
                {
                    "term": "Injuries, toxicosis, complications due to surgery",
                    "organSystem": "Injury, poisoning and procedural complications",
                    "notes": "Medication-related AE",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 86
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 84
                        },
                        {
                            "groupId": "EG002",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 85
                        }
                    ]
                },
                {
                    "term": "Muscular and connective tissue",
                    "organSystem": "Musculoskeletal and connective tissue disorders",
                    "notes": "Medication-related AE",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 86
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 84
                        },
                        {
                            "groupId": "EG002",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 85
                        }
                    ]
                },
                {
                    "term": "CNS disorders",
                    "organSystem": "Nervous system disorders",
                    "notes": "Medication-related AE",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 86
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 84
                        },
                        {
                            "groupId": "EG002",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 85
                        }
                    ]
                },
                {
                    "term": "Psychiatiric disorders",
                    "organSystem": "Psychiatric disorders",
                    "notes": "Medication-related AE",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 86
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 5,
                            "numAffected": 5,
                            "numAtRisk": 84
                        },
                        {
                            "groupId": "EG002",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 85
                        }
                    ]
                },
                {
                    "term": "Reproductive system and mammary gland",
                    "organSystem": "Reproductive system and breast disorders",
                    "notes": "Medication-related AE",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 86
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 84
                        },
                        {
                            "groupId": "EG002",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 85
                        }
                    ]
                },
                {
                    "term": "Respiratoty system, chest and mediastinum",
                    "organSystem": "Respiratory, thoracic and mediastinal disorders",
                    "notes": "Medication-related AE",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 86
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 84
                        },
                        {
                            "groupId": "EG002",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 85
                        }
                    ]
                },
                {
                    "term": "Dermatologic",
                    "organSystem": "Skin and subcutaneous tissue disorders",
                    "notes": "Medication-related AE",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 86
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 2,
                            "numAffected": 2,
                            "numAtRisk": 84
                        },
                        {
                            "groupId": "EG002",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 85
                        }
                    ]
                }
            ]
        },
        "moreInfoModule": {
            "certainAgreement": {
                "piSponsorEmployee": false,
                "restrictionType": "OTHER",
                "restrictiveAgreement": true
            },
            "pointOfContact": {
                "title": "Dr. Xianliang Xin",
                "organization": "Shanghai Greenvalley Pharmaceutical Co., Ltd.",
                "email": "xinxianliang@hotmail.com",
                "phone": "86 21-50504988",
                "phoneExt": "1370"
            }
        }
    },
    "target_category": "disease-targeted biologic",
    "drug": [
        "sodium oligo-mannurarate",
        "sodium oligomannate",
        "GV-971",
        "sodium oligomannurate"
    ],
    "placebo": [
        "placebo"
    ],
    "explanation_target": [
        "Reason: The investigational product named in the trial (sodium oligo-mannurarate) is the agent known as sodium oligomannate (GV-971), a marine-derived oligosaccharide being developed for mild-to-moderate Alzheimer disease. Preclinical and clinical reports describe GV-971 as inhibiting A\u03b2 aggregation/destabilizing A\u03b2 fibrils and also reconditioning gut microbiota to reduce peripheral immune infiltration and neuroinflammation \u2014 mechanisms directed at Alzheimer\u2019s pathology and cognition rather than only symptomatic (psychiatric) management. \ue200cite\ue202turn0search0\ue202turn0search1\ue202turn0search5\ue201",
        "Act: Key extracted trial details \u2014 Phase II study of \"sodium oligo-mannurarate capsule\" (synonymous with sodium oligomannate / GV-971) in mild-to-moderate AD; tested doses included 600 mg and 900 mg vs placebo with cognitive endpoints (ADAS\u2011cog and related scales). The intended effect in the protocol and published phase II/III reports is cognitive improvement via reduction of AD pathology and neuroinflammation. Based on those features, the trial drug is disease-targeting. \ue200cite\ue202turn0search6\ue202turn0search0\ue202turn0search1\ue201",
        "Reflect: Classification decision and uncertainty \u2014 GV-971 clearly targets AD pathophysiology (A\u03b2 aggregation and neuroinflammation) and was tested for disease-related cognitive effects, so it fits the \"disease-targeted\" part of the categories. Because GV-971 is a biologically derived oligosaccharide (a seaweed-derived oligosaccharide mixture), the closest of the provided categories is \"disease-targeted biologic.\" Note: regulatory sources describe GV-971 as a chemical drug for registration purposes (NMPA classification noted in post\u2011marketing descriptions), so one could argue a case for \"disease-targeted small molecule\" on the basis of regulatory classification. Given your categories and the compound's biological origin and mechanism aimed at pathology, I classify it as \"disease-targeted biologic.\" \ue200cite\ue202turn1search0\ue202turn0search1\ue201",
        "Web-search evidence (selected sources used to identify drug, mechanism, and trial design):",
        "- Phase II randomized trial report (describes 24\u2011week Phase II testing of GV\u2011971, doses 600/900 mg vs placebo; mechanism notes A\u03b2 aggregation inhibition and gut\u2011microbiota/neuroinflammation effects). \ue200cite\ue202turn0search0\ue202turn0search6\ue201",
        "- Phase III multicenter randomized trial (36\u2011week trial showing cognitive benefit on ADAS\u2011cog; summarizes proposed mechanism \u2014 marine\u2011derived oligosaccharide acting on gut microbiota and A\u03b2). \ue200cite\ue202turn0search1\ue201",
        "- Mechanistic/biophysical studies showing GV\u2011971 binds A\u03b2 and blocks aggregation (biochemical evidence supporting direct A\u03b2 interaction). \ue200cite\ue202turn0search5\ue201",
        "- Preclinical immunology/gut\u2011brain mechanism studies (GV\u2011971 alters gut microbiota, reduces peripheral Th1 inflammation and brain neuroinflammation in AD models). \ue200cite\ue202turn0search3\ue201",
        "- Regulatory/registry and company sources noting NMPA (China) conditional approval in Nov 2019 and post\u2011marketing/registration details. (These note NMPA approval and that the product is used/registered for mild\u2011to\u2011moderate AD in China.) \ue200cite\ue202turn1search0\ue202turn1search4\ue201"
    ],
    "agent_type": "R) Multi-target",
    "explanation_agent": [
        "Reason: The investigational drug sodium oligomannate (GV\u2011971) has two principal, distinct disease\u2011directed mechanisms reported in preclinical and clinical literature: direct electrostatic binding to A\u03b2 and inhibition/destabilization of A\u03b2 aggregation, and modulation of gut microbiota leading to reduced peripheral immune infiltration and CNS neuroinflammation \u2014 i.e., effects on both amyloid pathology and inflammation. \ue200cite\ue202turn1search2\ue202turn0search2\ue201",
        "Act: Key extracted details from the trial description and literature \u2014 Phase II randomized study of sodium oligomannate (GV\u2011971) in mild\u2011to\u2011moderate AD tested 600 mg and 900 mg vs placebo with cognitive endpoints (ADAS\u2011cog etc.). Mechanistic and biochemical studies show GV\u2011971 electrostatically binds A\u03b2 and blocks aggregation, and independent preclinical work shows GV\u2011971 alters gut microbiota and reduces neuroinflammation. GV\u2011971 was also granted conditional / priority approval in China (NMPA) for mild\u2011to\u2011moderate AD. \ue200cite\ue202turn0search0\ue202turn1search2\ue202turn0search2\ue202turn0search4\ue201",
        "Decision (Acting on CADRO): Because the agent has documented, mechanistically\u2011distinct actions on amyloid aggregation (CADRO A: Amyloid beta) and on neuroinflammation via the gut\u2011brain / immune axis (CADRO F: Inflammation), the most appropriate CADRO assignment is R) Multi\u2011target (captures agents intentionally affecting >1 CADRO domain).",
        "Reflect: I verified the classification against CADRO definitions \u2014 the trial drug is not purely symptomatic and does not fit a single CADRO category exclusively. Assigning R) Multi\u2011target best represents the documented dual mechanisms (amyloid + inflammation). If one had to force a single primary CADRO label, A) Amyloid beta could be argued because of direct A\u03b2 binding data; however the gut\u2011microbiota \u2192 immune \u2192 neuroinflammation pathway is an independent, disease\u2011relevant mechanism, supporting the multi\u2011target choice. \ue200cite\ue202turn1search2\ue202turn0search2\ue201",
        "Web search results used (selected, load\u2011bearing sources):",
        "- Phase II randomized clinical trial report (24\u2011week, GV\u2011971 600/900 mg vs placebo; cognitive endpoints). \ue200cite\ue202turn0search0\ue201",
        "- Biochemical/biophysical study showing GV\u2011971 electrostatically binds A\u03b2 and blocks aggregation. \ue200cite\ue202turn1search2\ue202turn1search4\ue201",
        "- Preclinical and mechanistic studies showing GV\u2011971 alters gut microbiota and reduces peripheral/brain neuroinflammation and amyloid pathology in animal models. \ue200cite\ue202turn0search2\ue201",
        "- Product/company / regulatory information including NMPA approval and product description (brain\u2013gut axis mechanism emphasized). \ue200cite\ue202turn0search5\ue202turn0search4\ue201"
    ]
}